loratadine has been researched along with fluoxetine in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 10 (47.62) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Keserü, GM | 1 |
| Caron, G; Ermondi, G | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Morphy, R; Rankovic, Z | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Jia, L; Sun, H | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Ang, KK; Arkin, MR; Chen, S; Doyle, PS; Engel, JC; McKerrow, JH | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Sen, S; Sinha, N | 1 |
| Freiwald, S; Jiang, Y; Jones, JP; Kaspera, R; Katayama, J; Lee, CA; Smith, E; Totah, RA; Walker, GS | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Mathews, J | 1 |
| Ackland, MJ; Alex, AA; de Groot, MJ; Horne, VA; Jones, BC | 1 |
| Brubaker, RV | 1 |
| Banfield, C; Flannery, B; Gupta, S; Herron, J; Kantesaria, B | 1 |
| Braun, A; Liang, SH; Ritter, T; Shi, H; Vasdev, N; Wang, L | 1 |
| Ahemad, N; Dong, AN; Ong, CE; Palanisamy, UD; Pan, Y; Yiap, BC | 1 |
2 review(s) available for loratadine and fluoxetine
| Article | Year |
|---|---|
Designed multiple ligands. An emerging drug discovery paradigm.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Chemistry, Pharmaceutical; Dopamine D2 Receptor Antagonists; Drug Design; Humans; Ligands; Metabolic Diseases; Peroxisome Proliferator-Activated Receptors; Receptors, Histamine H1; Selective Serotonin Reuptake Inhibitors | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for loratadine and fluoxetine
| Article | Year |
|---|---|
Pharmacokinetics/pharmacodynamics of desloratadine and fluoxetine in healthy volunteers.
Topics: Adolescent; Adult; Anti-Allergic Agents; Area Under Curve; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Electrocardiography; Female; Fluoxetine; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors | 2004 |
18 other study(ies) available for loratadine and fluoxetine
| Article | Year |
|---|---|
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
Topics: 1-Octanol; Alkanes; Hydrogen-Ion Concentration; Least-Squares Analysis; Mathematics; Models, Chemical; Models, Molecular; Solvents; Water | 2005 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
Topics: Animals; Cattle; Cell Line; Cell Line, Tumor; Chagas Disease; Drug Evaluation, Preclinical; Hepatocytes; High-Throughput Screening Assays; Humans; Image Processing, Computer-Assisted; Muscle, Skeletal; Parasitic Sensitivity Tests; Trypanocidal Agents; Trypanosoma cruzi | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
Topics: Amiodarone; Astemizole; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Danazol; Drug Discovery; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Methylation; Microsomes, Liver; Models, Biological; Molecular Structure; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Concern over Prozac-induced tumor growth may dwindle following FDA study.
Topics: Amitriptyline; Animals; Depression; Fluoxetine; Humans; Loratadine; Neoplasms; Recurrence; United States; United States Food and Drug Administration | 1995 |
A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Betaxolol; Cytochrome P-450 CYP2D6; Dealkylation; Fluoxetine; Loratadine; Models, Molecular; Pharmaceutical Preparations; Procainamide; Ritonavir; Substrate Specificity; Sumatriptan | 1999 |
Fluoxetine-induced sexual dysfunction reversed by loratadine.
Topics: Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoxetine; Histamine H1 Antagonists; Humans; Loratadine; Male; Sexual Dysfunctions, Psychological; Treatment Outcome | 2002 |
Synthesis of (18) F-Difluoromethylarenes from Aryl (Pseudo) Halides.
Topics: Acetamides; Fluorine Radioisotopes; Fluoxetine; Halogenation; Isotope Labeling; Loratadine; Phenyl Ethers; Positron-Emission Tomography; Radiopharmaceuticals | 2016 |
The Molecular and Enzyme Kinetic Basis for Altered Activity of Three Cytochrome P450 2C19 Variants Found in the Chinese Population.
Topics: Alleles; Amino Acid Sequence; Asian People; Catalytic Domain; Coumarins; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Fluoxetine; Humans; Ketoconazole; Kinetics; Loratadine; Models, Molecular; Molecular Docking Simulation; Mutagenesis, Site-Directed; Nitriles; Omeprazole; Polymorphism, Genetic; Protein Conformation; Protein Isoforms; Recombinant Proteins; Sertraline; Substrate Specificity | 2020 |